Alicia Clawson
About
Alicia Clawson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Alicia Clawson has authored 30 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Molecular Biology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alicia Clawson's work include Cancer Treatment and Pharmacology (14 papers), HER2/EGFR in Cancer Research (9 papers) and Chromatin Remodeling and Cancer (7 papers). Alicia Clawson is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), HER2/EGFR in Cancer Research (9 papers) and Chromatin Remodeling and Cancer (7 papers). Alicia Clawson collaborates with scholars based in United States, France and United Kingdom. Alicia Clawson's co-authors include Sergey Cheporov, D. Krasnojon, G. Manikhas, Paul Bhar, А. Н. Махсон, William J. Gradishar, Peter Ho, Antoîne Italiano, Stephen J. Blakemore and Scott Ribich and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer.
In The Last Decade
Alicia Clawson
30 papers receiving 1.4k citations
Hit Papers
Peers
Alicia Clawson
Gayle Jameson United States
А. Н. Махсон Russia
Kamalesh K. Sankhala United States
Vicki L. Keedy United States
Darren Sigal United States
Ymera Pignochino Italy
Robert Calaluce United States
Dominic Fong Austria
O.O. Melnyk United States
Sanjun Cai China
Citations per year, relative to Alicia Clawson Alicia Clawson (= 1×)
peers
Gayle Jameson
Countries citing papers authored by Alicia Clawson
Since
Specialization
Citations
This map shows the geographic impact of Alicia Clawson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alicia Clawson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alicia Clawson more than expected).
Fields of papers citing papers by Alicia Clawson
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Alicia Clawson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alicia Clawson. The network helps show where Alicia Clawson may publish in the future.
Co-authorship network of co-authors of Alicia Clawson
This figure shows the co-authorship network connecting the top 25 collaborators of Alicia Clawson. A scholar is included among the top collaborators of Alicia Clawson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alicia Clawson. Alicia Clawson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Loomba, Rohit, Kris V. Kowdley, José R Rodríguez-Medina, et al.. (2025). Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet. Gastroenterology & hepatology. 10(8). 734–745.
2.
Kowdley, Kris V., Alicia Clawson, Tatjana Odrljin, et al.. (2025). 723: ONCE-MONTHLY EFIMOSFERMIN ALFA (BOS-580) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS WITH F2/F3 FIBROSIS: RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL. Gastroenterology. 169(1). S–1647.
3.
Loomba, Rohit, Kris V. Kowdley, José R Rodríguez-Medina, et al.. (2023). Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: a randomized, blinded, placebo-controlled phase 2A trial. Journal of Hepatology. 78. S115–S116.
4.
Schöffski, Patrick, Byoung Chul Cho, Antoîne Italiano, et al.. (2021). BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results.. Journal of Clinical Oncology. 39(15_suppl). 3008–3008.
5.
Daigle, Scott R., Silvia Stacchiotti, Patrick Schöffski, et al.. (2018). Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase II study of tazemetostat (NCT02601950). Annals of Oncology. 29. viii670–viii670.
6.
Italiano, Antoîne, Jean‐Charles Soria, Maud Toulmonde, et al.. (2018). Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. The Lancet Oncology. 19(5). 649–659.
7.
Stacchiotti, Silvia, Jean‐Yves Blay, Robin L. Jones, et al.. (2018). A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). Annals of Oncology. 29. viii580–viii580.
8.
Jones, Robin L., Jean‐Yves Blay, Mark Agulnik, et al.. (2018). A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950). Annals of Oncology. 29. viii580–viii581.
9.
Zauderer, Marjorie G., Peter W. Szlosarek, Sylvestre Le Moulec, et al.. (2018). Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.. Journal of Clinical Oncology. 36(15_suppl). 8515–8515.
10.
Gounder, Mrinal M., Silvia Stacchiotti, Patrick Schöffski, et al.. (2017). Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).. Journal of Clinical Oncology. 35(15_suppl). 11058–11058.
11.
Schöffski, Patrick, Mark Agulnik, Silvia Stacchiotti, et al.. (2017). Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma (NCT02601950).. Journal of Clinical Oncology. 35(15_suppl). 11057–11057.
12.
Seidman, Andrew D., Alison Conlin, Ariadne M. Bach, et al.. (2013). Randomized Phase II Trial of Weekly vs. Every 2 Weeks vs. Every 3 Weeks Nanoparticle Albumin-Bound Paclitaxel With Bevacizumab as First-Line Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer. 13(4). 239–246.e1.
13.
Gradishar, William J., D. Krasnojon, Sergey Cheporov, et al.. (2012). Phase II Trial of Nab-Paclitaxel Compared With Docetaxel as First-Line Chemotherapy in Patients With Metastatic Breast Cancer: Final Analysis of Overall Survival. Clinical Breast Cancer. 12(5). 313–321.
14.
Pippen, John, Devchand Paul, Svetislava J. Vukelja, Alicia Clawson, & José Iglesias. (2011). Dose-dense doxorubicin and cyclophosphamide followed by dose-dense albumin-bound paclitaxel plus bevacizumab is safe as adjuvant therapy in patients with early stage breast cancer. Breast Cancer Research and Treatment. 130(3). 825–831.
15.
Conlin, Alison, Andrew D. Seidman, Ariadne M. Bach, et al.. (2010). Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer. 10(4). 281–287.
16.
Robert, Nicholas J., et al.. (2010). Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study. Breast Cancer Research and Treatment. 125(1). 115–120.
17.
Conlin, Alison, C. Hudis, A M Bach, et al.. (2009). Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1006–1006.
18.
Hersh, Evan M., Steven O’Day, Antoni Ribas, et al.. (2009). A phase 2 clinical trial of nab‐paclitaxel in previously treated and chemotherapy‐naive patients with metastatic melanoma. Cancer. 116(1). 155–163.
19.
Gradishar, WJ, D. Krasnojon, Sergey Cheporov, et al.. (2008). Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC). European Journal of Cancer Supplements. 6(7). 172–172.
20.
Blum, Joanne L., Michael A. Savin, Gerald M. Edelman, et al.. (2007). Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes. Clinical Breast Cancer. 7(11). 850–856.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Gayle Jameson Breakdown of academic impact, for papers by А. Н. Махсон Breakdown of academic impact, for papers by Kamalesh K. Sankhala Breakdown of academic impact, for papers by Vicki L. Keedy Breakdown of academic impact, for papers by Darren Sigal Breakdown of academic impact, for papers by Ymera Pignochino Breakdown of academic impact, for papers by Robert Calaluce Breakdown of academic impact, for papers by Dominic Fong Breakdown of academic impact, for papers by O.O. Melnyk Breakdown of academic impact, for papers by Sanjun Cai